Puma Biotechnology Inc

Most Recent

  • uploads///thermometer headache pain pills
    Company & Industry Overviews

    ASCO 2019 Presentations: Late-Stage Breast Cancer Trials

    The annual ASCO (American Society of Clinical Oncology) 2019 meeting will be held on May 31–June 4 in Chicago.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Analysts Expect Puma Biotechnology to Become Profitable in 2020

    In its first-quarter earnings conference call, Puma Biotechnology (PBYI) highlighted its cash burn of $15 million in the first quarter.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Puma Biotechnology Reduced Guidance for NERLYNX Sales

    During its first-quarter earnings conference call, Puma Biotechnology (PBYI) reduced its guidance for fiscal 2019 net sales of NERLYNX in the US market.

    By Margaret Patrick
  • uploads///hand _
    Earnings Report

    What Analysts Are Recommending for Puma Biotechnology

    On May 10, Puma Biotechnology (PBYI) reported its first-quarter results.

    By Margaret Patrick
  • uploads///medic _
    Company & Industry Overviews

    Why Clovis Oncology Stock Rose 48% in November

    On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results

    On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    NERLYNX: Market Expansion and Label Expansion

    Puma Biotechnology is studying NERLYNX in a Phase 3 NALA trial in the third line HER2-positive metastatic breast cancer indication.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    NERLYNX: Major Growth Driver for PBYI

    Puma Biotechnology (PBYI) reported net sales of $52.6 million for NERLYNX in the third quarter.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Puma Biotechnology: Revenue Projections for 2018

    Puma Biotechnology expects NERLYNX’s net product revenues to be $175 million–$200 million for 2018.

    By Margaret Patrick
  • uploads///dna _
    Company & Industry Overviews

    Puma Biotechnology Enters into Collaboration with Strata Oncology

    Puma Biotechnology and Strata Oncology are collaborating to evaluate the safety and efficacy of the kinase inhibitor drug neratinib.

    By Daniel Collins
  • uploads///lab _
    Company & Industry Overviews

    How Analysts Are Rating Puma Biotechnology in July

    On July 5, Puma Biotechnology (PBYI) stock closed at $58.75, which represents a 25% growth from its 52-week low of $47 on June 7.

    By Daniel Collins
  • uploads///Perjeta
    Company & Industry Overviews

    Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018

    In December 2017, the Food and Drug Administration approved Roche’s (RHHBY) Perjeta based on the results of its phase three Aphinity trial.

    By Daniel Collins
  • uploads///Spectrum Pharmaceuticals Revenue Trend
    Company & Industry Overviews

    Chart in Focus: Spectrum Pharmaceuticals’ Financials

    In 3Q17, Spectrum Pharmaceuticals (SPPI) raised $114.0 million from the sale of 12.6 million shares through its security offering program.

    By Kenneth Smith
  • uploads///Spectrum Pharmaceuticals Pipeline
    Company & Industry Overviews

    An Overview of Spectrum Pharmaceuticals’ Drug Pipeline

    Spectrum Pharmaceuticals (SPPI) obtained exclusive rights to commercialize Poziotinib from Hanmi Pharmaceutical (HANPF) under an in-license agreement in 2015.

    By Kenneth Smith
  • uploads///Analysts Ratings for Spectrum Pharmaceuticals
    Company & Industry Overviews

    Analysts’ Recommendations for Spectrum Pharmaceuticals

    Biotech firm Spectrum Pharmaceuticals (SPPI) develops oncology and hematology drug products. SPPI generates ~90% of its revenues from the US market, and ~10% of its revenues come from Europe.

    By Kenneth Smith
  • uploads///Graph Part
    Company & Industry Overviews

    XBI’s Top Ten Small-Cap Stocks Perform on Par with Large-Caps

    In the small-cap space, the top ten stocks of XBI had an average return of -12.18% for the week ended September 25, 2015. This is similar to XBI’s top ten large-cap stocks that returned -12.15%.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    XBI Moving Averages Are on the Rise

    For the week ended September 11, 2015, the SPDR S&P Biotechnology ETF (XBI) saw a big jump in the number of stocks trading above the 20-day moving average.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.